Fetuin A in Hashimoto Thyroiditis
Fetuin A as a New Marker of Inflammation in Hashimoto Thyroiditis
1 other identifier
observational
97
0 countries
N/A
Brief Summary
Fetuin-A levels are reported to be low as a negative acute phase reactant in systemical inflammatory situations. Hashimoto thyroiditis is characterized with inflammation. In this study, we hypothesised that the serum fetuin A levels could be found to be low due to inflammation in patients with Hashimoto thyroiditis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2012
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2012
CompletedFirst Submitted
Initial submission to the registry
June 17, 2013
CompletedFirst Posted
Study publicly available on registry
June 24, 2013
CompletedJune 24, 2013
June 1, 2013
5 months
June 17, 2013
June 21, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Comparison of serum fetuin A levels between patients with Hashimoto thyroiditis and healthy subjects
1 day (The blood samples were obtained on the same day participants arrived to outpatient clinics.)
Study Arms (2)
Group of Hashimoto thyroiditis patients
Healty control group
Eligibility Criteria
Patients ≥ 20 years of age being followed up at the outpatient clinics of the Internal Medicine Department in Medeniyet University Goztepe Training and Research Hospital and fulfilling the below mentioned criteria were included in the study
You may qualify if:
- patients newly diagnosed with Hashimoto thyroiditis
You may not qualify if:
- Acute infection
- Acute or chronic inflammatory disease
- Anti-inflammatory treatment (non-steroidal anti-inflammatory, corticosteroids etc.)
- Hypoxic situations (chronic obstructive pulmonary disease etc.)
- Severe heart, kidney and liver disease
- Pregnancy
- Endocrine disorders
- Malignancy
- Usage of drug that affects thyroid hormone levels
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 1 Day
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D.
Study Record Dates
First Submitted
June 17, 2013
First Posted
June 24, 2013
Study Start
May 1, 2012
Primary Completion
October 1, 2012
Study Completion
October 1, 2012
Last Updated
June 24, 2013
Record last verified: 2013-06